Leerink Partners Cuts Price Target on Mirna Therapeutics (MIRN) Following 4Q Updates
Tweet Send to a Friend
Leerink Partners maintained an Outperform rating on Mirna Therapeutics (NASDAQ: MIRN), and cut the price target to $10.00 (from $14.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
